Knoll Capital Management’s Elicio Therapeutics ELTX Stock Holding History

Knoll Capital Management’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.74M	Buy	1,211,957 +581,042	+92%	+$5.83M	2.64%	16
2026 Q1	$6.74M	Hold	630,915	–	–	3.74%	11
2025 Q4	$5.02M	Hold	630,915	–	–	2.3%	18
2025 Q3	$6.9M	Hold	630,915	–	–	3.7%	12
2025 Q2	$4.87M	Hold	630,915	–	–	3.46%	10
2025 Q1	$3.89M	Buy	+630,915	New	+$4.89M	2.53%	13
2022 Q3	–	Sell	-6,000	Closed	-$68K	–	37
2022 Q2	$68K	Hold	6,000	–	–	0.04%	40
2022 Q1	$127K	Hold	6,000	–	–	0.08%	40
2021 Q4	$174K	Hold	6,000	–	–	0.1%	38
2021 Q3	$586K	Hold	6,000	–	–	0.29%	26
2021 Q2	$781K	Hold	6,000	–	–	0.41%	28
2021 Q1	$1.08M	Buy	+6,000	New	+$1.16M	0.71%	20

Other funds holding ELTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Knoll Capital Management's ELTX Position: Q2 2026 in Review

Knoll Capital Management increased its Elicio Therapeutics (ELTX) stake by 92% in Q2 2026, buying an estimated $5.83M and bringing the position to 1,211,957 shares worth $4.74M. The position accounts for 2.64% of the portfolio, ranked #16.

Knoll Capital Management first reported a position in ELTX in Q1 2021 and has held it in 12 quarters since. The position peaked at $6.9M in Q3 2025. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Knoll Capital Management held 1,211,957 shares of Elicio Therapeutics worth $4.74M as of Q2 2026.
Knoll Capital Management bought 581,042 Elicio Therapeutics shares in Q2 2026, an estimated $5.83M.
Elicio Therapeutics made up 2.64% of Knoll Capital Management's portfolio in Q2 2026, its #16 holding.
Knoll Capital Management first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 12 quarters since.
Knoll Capital Management's Elicio Therapeutics position peaked at $6.9M in Q3 2025.
48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Knoll Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.